Maxcyte (MXCT) Return on Sales (2020 - 2026)

Maxcyte (MXCT) has 7 years of Return on Sales data on file, last reported at 0.0% in Q1 2026.

• Quarterly Return on Sales rose 1.0% year-over-year to 0.0% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 0.02% (down 1.0% YoY) and the FY2025 annual result came in at 0.02%, down 1.0% from the prior year.
• Return on Sales fell to 0.0% in Q1 2026 per MXCT's latest filing, from 0.02% in the prior quarter.
• Across five years, Return on Sales topped out at 0.02% in Q4 2025 and bottomed at 0.03% in Q3 2023.
• The 5-year median for Return on Sales is 0.01% (2024), against an average of 0.01%.
• The widest annual swing landed in 2023, when Return on Sales slipped 3 bps; it then advanced 3 bps in 2025.
• Tracing MXCT's Return on Sales over 5 years: stood at 0.02% in 2022, then plunged by 171 bps to 0.01% in 2023, then slipped by 10 bps to 0.01% in 2024, then surged by 265 bps to 0.02% in 2025, then plunged by 124 bps to 0.0% in 2026.
• Per Business Quant, the three latest MXCT Return on Sales figures stand at 0.0% (Q1 2026), 0.02% (Q4 2025), and 0.02% (Q3 2025).

Peer Comparison